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Abstract
The gram-negative opportunistic pathogen Pseudomonas aeruginosa is the primary cause of chronic respiratory
infections in individuals with the heritable disease cystic fibrosis (CF). These infections can last for decades, during
which time P. aeruginosa has been proposed to acquire beneficial traits via adaptive evolution. Because CF lacks an
animal model that can acquire chronic P. aeruginosa infections, identifying genes important for long-term in vivo
fitness remains difficult. However, since clonal, chronological samples can be obtained from chronically infected
individuals, traits undergoing adaptive evolution can be identified. Recently we identified 24 P. aeruginosa gene
expression traits undergoing parallel evolution in vivo in multiple individuals, suggesting they are beneficial to the
bacterium. The goal of this study was to determine if these genes impact P. aeruginosa phenotypes important for
survival in the CF lung. By using a gain-of-function genetic screen, we found that 4 genes and 2 operons undergoing
parallel evolution in vivo promote P. aeruginosa biofilm formation. These genes/operons promote biofilm formation by
increasing levels of the non-alginate exopolysaccharide Psl. One of these genes, phaF, enhances Psl production via
a post-transcriptional mechanism, while the other 5 genes/operons do not act on either psl transcription or
translation. Together, these data demonstrate that P. aeruginosa has evolved at least two pathways to over-produce
a non-alginate exopolysaccharide during long-term colonization of the CF lung. More broadly, this approach allowed
us to attribute a biological significance to genes with unknown function, demonstrating the power of using evolution
as a guide for targeted genetic studies.
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Introduction
Chronic infections are an especially difficult healthcare
problem because pathogens persist in the host despite
therapeutic treatment. Due to a genetic defect, individuals with
the heritable disease cystic fibrosis (CF) are prone to chronic,
fatal respiratory infections caused by the Gram-negative
opportunistic pathogen Pseudomonas aeruginosa [1]. During
chronic infection, P. aeruginosa undergoes adaptation in the
CF lung, which is thought to enhance the fitness of this
bacterium in vivo [2,3]. Therefore, identifying fitness traits in
chronic CF strains is important for designing novel treatment
strategies, but this problem is challenging because animal
models that recapitulate chronic P. aeruginosa CF infections do
not currently exist.
One means of overcoming this challenge is to utilize an
evolutionary approach to identify beneficial adaptations.
Chronic CF infections are well suited for evolutionary studies
because they are typically dominated by a single P. aeruginosa
strain allowing clonal, chronological isolates to be sampled
over decades-long time periods [4]. Beneficial adaptations can
be determined by 1) identifying parallel genotypes and
phenotypes that arise within multiple P. aeruginosa lineages, a
strong indicator of adaptive evolution and 2) using whole-
genome sequencing to identify evidence for positive selection.
Indeed, phenotypic studies have shown that P. aeruginosa
frequently undergoes parallel changes in vivo, one of the most
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well understood being conversion to the mucoid phenotype [5].
This phenotype is characterized by over-production of the
exopolysaccharide alginate, which enhances biofilm formation
[6]. Prevalence of mucoid isolates is on average reported as
~41% [4,7,8], though one study reported 80% [9]. These data
suggest that other important adaptive traits likely arise in vivo.
Additionally, genome sequencing has demonstrated adaptation
occurring during the first 40,000 of up to 200,000 generations
in vivo [2,3]. This initial period of adaptation is followed by a
longer period of genetic drift and negative selection [3],
suggesting that adaptive traits are likely to arise during initial
phases (~40,000 generations) of chronic infection.
We previously used an evolutionary approach to identify P.
aeruginosa gene expression traits likely undergoing adaptive
evolution in vivo [10]. P. aeruginosa was chronologically
sampled from 3 CF patients, ranging from the first infecting
bacterium (the ancestor) to ~40,000 generations post-infection.
By comparing gene expression profiles of early and late
isolates sampled from multiple patients, we identified 24
parallel gene expression changes that occurred over time
within each lineage. These data strongly indicate that these
gene expression traits are undergoing adaptive evolution and
therefore benefit the bacterium during chronic infection.
Of these 24 genes, 15 were up-regulated in chronic isolates
compared to their ancestor; however, the phenotypic
consequences associated with these gene expression changes
were unclear. Several of these genes were previously
associated with biofilm formation, a sessile mode of growth
prominent in the CF lung presumably due to its protective
effects against antibiotics and host defenses [11-14]. We
therefore hypothesized that a portion of these genes would
promote enhanced biofilm formation. To test this hypothesis,
we performed a gain-of-function screen to determine the
impact of these up-regulated genes on biofilm formation. Our
results reveal that expression of 4 genes and 2 operons
increases biofilm formation via enhancing levels of the P.
aeruginosa exopolysaccharide Psl. One of the genes, the
transcriptional regulator phaF, enhances Psl levels via a post-
transcriptional mechanism, while the other genes enhance Psl
production but do not affect either psl transcription or
translation. Finally, we show that within the first ~40,000
generations of chronic infection, Psl production increases in
~72% of chronic CF isolates compared to their ancestor. These
data indicate that enhanced production of Psl is an important
adaptation during the first ~40,000 generations of P.
aeruginosa growth in the CF lung and that multiple pathways
evolved to impact this trait.
Materials and Methods
Bacterial strains and growth media
The bacterial strains used in this study are listed in Tables
S3 and S4. Escherichia coli was routinely grown on Luria-
Bertani medium at 37°C. P. aeruginosa strains were grown at
37°C on tryptic soy broth/agar medium,
morpholinepropanesulfonic acid (MOPS)-buffered medium (50
mM MOPS [pH 7.2], 93 mM NH4Cl, 43 mM NaCl, 3.7 mM
KH2PO4, 1 mM MgSO4, and 3.5 μM FeSO47H2O) supplemented
with 0.5% glucose and 0.5% casamino acids, or a previously
described Synthetic Cystic Fibrosis Medium (SCFM) [15].
When applicable, antibiotics were used at the following
concentrations: 10 μg/ml and 25 μg/ml gentamicin for
maintenance and selection, respectively, in E. coli and 50
μg/ml and 100 μg/ml gentamicin for maintenance and
selection, respectively, in P. aeruginosa.
DNA and plasmid manipulations
The primers used in this study are listed in Table S5.
Standard methods were used for DNA and plasmid
manipulations.
Strain construction
A non-polar deletion of pslA in PAO1 was constructed using
allelic replacement and sacB counter-selection as previously
described [16]. pslA-lacZ transcriptional and translational
fusions were a generous gift from Dr. Yasuhiko Irie and were
introduced onto the chromosome at the attB site as previously
described [17]. Allelic replacement and chromosomal
integrations were confirmed via PCR analyses and DNA
sequencing.
Microtiter dish biofilm assay
Microtiter dish biofilm assays were performed as previously
described with minor modifications [18]. Strains were grown in
MOPS minimal media supplemented with 0.5% glucose and
0.5% casamino acids. Overnight P. aeruginosa cultures were
diluted to OD600=1.0 in MOPS minimal medium, and 5 μl was
used to inoculate 95 μl media (final OD600=0.05) in a 96-well
polystyrene microtiter dish (NUNC). Each well contained a 3
mm borosilicate glass bead for aeration. Microtiter dishes were
sealed with parafilm and incubated at 37°C with 250 r.p.m.
shaking. Staining with 0.1% crystal violet was performed at 12
h, followed by washing and dye solubilization with 33% acetic
acid. Absorbance was measured at 620 nm. Strains were
grown in octuplicate and at least 3 biological replicates were
performed.
Microarray analyses
The empty vector control strain and the phaF over-
expression strain were grown in 250 ml flasks in 25 ml MOPS
minimal media supplemented with 0.5% glucose and 0.5%
casamino acids. RNA was prepared from cells grown to
OD600=0.9-1.0. Clinical isolates and PAO1 were grown in
SCFM and RNA was prepared from cells grown to
OD600=0.4-0.5 [10]. RNA extraction, cDNA synthesis,
hybridization, and downstream data analyses were performed
as previously described [10,15]. Genes were considered
differentially expressed if they exhibited a greater than 2-fold
change and a false discovery rate (FDR) < 0.05.
Psl immunoblots
Psl immunoblots were carried out as previously described
with minor modifications [19]. Stationary phase cultures were
diluted to a final OD600=~0.05 in 5 ml MOPS minimal media
supplemented with 0.5% glucose and 0.5% casamino acids or
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SCFM. Cultures were grown for approximately 16 h, and either
10 OD equivalents (volume [ml] = 10/culture OD600) or whole
cultures were harvested. Cell pellets were re-suspended in 100
μl of 0.5 M EDTA, boiled at 100°C for 30 minutes, and
centrifuged. The supernatant fraction was treated with
proteinase K (final concentration 5 mg/ml) for 1 h at 60°C,
followed by inactivation for 30 minutes at 80°C. Samples were
stored at 4°C for Psl immunoblotting. Pelleted lysate was re-
suspended in 1 ml 6 M urea and boiled for 1 h at 100°C.
Protein concentration was measured via Bradford assay (Bio-
Rad). Crude polysaccharide preparations were normalized to
equal protein concentrations by diluting samples in 0.5 M
EDTA. 20-30 μl of polysaccharide preparation was spotted onto
a nitrocellulose membrane using a dot blot apparatus. Blocking
was performed in 10% skim milk in TBST (20 mM Tris, 137 mM
NaCl, 0.1% Tween 20, pH 7.6) followed by probing with α-Psl
antiserum (1:25,000 in TBST) for 45 minutes at 25°C with
agitation. After washing, the membrane was incubated with
horseradish peroxidase (HRP)-conjugated goat anti-rabbit
secondary antibody (1:10,000 in TBST; Bio-Rad) for 1 h at
room temperature. The membrane was washed and developed
using SuperSignal West Dura Extended Duration Substrate
following the manufacturer’s instructions (Pierce). At least 3
biological replicates were performed for each strain.
β-galactosidase assays
P. aeruginosa strains were grown as described above. 1 ml
culture aliquots were removed at exponential (OD600=0.5-1.0)
and stationary phase (~16 hours) for β-galactosidase
measurements. Cells were pelleted, re-suspended in 1 ml Z-
buffer + 2-mercaptoethanol, lysed with 200 μl chloroform, and
equilibrated for 5 minutes. β-galactosidase activity was
measured using the Galacto-Light Plus System (Applied
Biosystems) and normalized to total protein as measured by
Bradford assay.
RNA preparation and Northern blot analyses
P. aeruginosa PAO1 strains were grown as described above
and cultures were mixed 1:1 (vol/vol) with RNAlater (Ambion).
Total RNA was purified using RNAbee following the
manufacturer’s protocol (Tel-Test). RNA samples were treated
with DNase to remove contaminating DNA following the
manufacturer’s protocol. Probe sequences are listed in Table
S5. Northern blot analyses were performed as previously
described [20].
Microarray data accession numbers
All microarray data are available at the NCBI GEO database.
The accession number for the microarrays comparing PAO1
and ancestor clinical isolates is GSE21966. The accession
number for the microarrays comparing the empty vector control
strain and the phaF over-expression strain is GSE47173.
Results
Over-expression of up-regulated genes enhances
biofilm formation
Recently we identified 24 P. aeruginosa gene expression
traits undergoing selection within the CF lung [10]. Fifteen of
the 24 genes were up-regulated in chronic isolates compared
to the ancestor (defined as the P. aeruginosa isolate initially
establishing the chronic infection), and their roles during
chronic infection are unknown. Some of these genes are
predicted to be part of an operon and have been associated
with biofilm formation in previous studies [11,13,14]. To test the
hypothesis that some of these up-regulated genes/operons
contribute to biofilm formation, we used a genetic approach to
test for gain-of-function phenotypes. Each gene or operon was
introduced into the laboratory strain P. aeruginosa PAO1 on a
low-copy plasmid and expressed from the arabinose-inducible
pBAD promoter [21]. This genetic system is relevant for
studying gain-of-function phenotypes because 1) the pBAD
promoter exhibits minimal expression without arabinose
inducer [21], allowing us to avoid non-specific cellular
responses caused by gene over-expression; 2) the PAO1
genome is sequenced and pathways impacting biofilm
formation are well characterized; and 3) microarray analyses
showed that expression of the 15 up-regulated genes are
comparable between PAO1 and ancestral clinical isolates
(Table S1). We conducted our experiments without arabinose
since this resulted in an approximate 3-4 fold increase in
expression, levels similar to those found in chronic clinical
isolates (Table S2). Expression of PA1106, PA1323-24,
PA1592, PA3691-92, phaF (PA5060), and PA5178 enhanced
biofilm formation relative to the empty vector control strain
(Figure 1A). While the phenotype is modest, similar increases
in biofilm formation have been reported [22]. As expected, a
negative control strain unable to initiate attachment, PAO1
ΔpslA pJN105, showed a significant biofilm defect (Figure 1A).
Among the genes and operons that enhanced biofilm
formation, only PA3692 (lptF) and phaF have known or
proposed functions. PA3692 is involved in adhesion to lung
epithelial cells, while phaF is a transcriptional regulator of
polyhydroxyalkanoate biosynthesis in Pseudomonas putida
[23,24]. The remaining biofilm-enhancing genes have
hypothetical functions.
Enhanced biofilm formation of P. aeruginosa requires
Psl
We next sought to determine the mechanism governing
enhanced biofilm formation. Although multiple pathways are
important for P. aeruginosa biofilm formation, we obtained an
important clue to the mechanism when one of the adapted
genes (phaF) was over-expressed in the P. aeruginosa
laboratory strain PA14. Surprisingly, this strain did not produce
more biofilm (Figure S1). Examination of the PAO1 and PA14
genomes revealed that PA14 does not encode the genetic
machinery required for production of the exopolysaccharide
Psl. Since Psl is important for biofilm formation in P.
aeruginosa, we hypothesized that enhanced biofilm formation
of PAO1 over-expressing phaF, and potentially the other
Pseudomonas aeruginosa Adaptation in the CF Lung
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adapted genes, involves Psl production. To test this
hypothesis, we expressed the adapted genes/operons in a
PAO1 strain that lacks the ability to produce Psl (ΔpslA) and
tested these strains for biofilm formation (Figure 1B). As in
PA14, phaF expression did not enhance biofilm formation in
ΔpslA. Notably, the other 5 strains also did not form more
biofilm than the empty vector control strain, ΔpslA pJN105
(Figure 1B), suggesting that these 6 genes/operons enhance
biofilm formation in a Psl-dependent manner.
Up-regulated genes induce Psl production
If Psl is required for enhanced biofilm formation in the over-
expression strains, each should correspondingly produce more
Psl. We therefore used immunoblot analyses to measure Psl
production in all 14 of our over-expression strains. First, Psl
anti-sera specificity was demonstrated with a strain that cannot
produce Psl (WFPA800) [19], an arabinose-inducible psl over-
expression strain (WFPA801) [19], and the wild-type empty
vector control strain PAO1 pJN105 (Figure S2). To determine
the effect of each gene/operon on Psl production, crude
polysaccharide extracts from each over-expression strain were
subjected to anti-Psl immunoblot analyses. PAO1 ΔpslA
 carrying the empty vector served as the negative control, and
as expected, Psl was not detected (Figure 1C). As predicted
from our biofilm results, over-expression strains PA1106,
PA1323-24, PA1592, PA3691-92, phaF, and PA5178 produced
more Psl than the empty vector control strain (Figure 1C).
Importantly, increased Psl is not an artificial response to gene
over-expression, as 8 over-expression strains did not show
enhanced biofilm formation or Psl production. These data along
with the fact that enhanced biofilm formation does not occur in
PAO1 ΔpslA suggests that these 6 genes/operons enhance
biofilm formation through increased production of the
exopolysaccharide Psl.
phaF regulates Psl production post-transcriptionally
Although over-expression of 6 adapted genes/operons
enhanced biofilm formation via increased Psl production, it was
unclear whether these genes/operons acted within the same or
different pathways. P. aeruginosa regulates Psl both
transcriptionally and post-transcriptionally [17,25], allowing us
to test whether these genes/operons affect Psl levels via the
same pathway. We constructed strains containing previously
characterized chromosomal pslA-lacZ transcriptional or
Figure 1.  Biofilm formation and Psl production in over-expression strains.  (A) Fold change in biofilm formation of wild-type
PAO1 over-expression strains. Bars represent the average fold change in biofilm formation compared to the empty vector control
strain, PAO1 pJN105 (dashed line). ΔpslA pJN105, a strain that cannot produce Psl, served as a negative control. While fold
change in biofilm formation is reported for clarity, statistics were performed on absorbance values for empty vector control and over-
expression strains assayed on the same day. At least 3 biological replicates were performed in octuplicate. *, P value < 0.001 by
Student’s t test. Error bars represent standard error of the mean, n=3. (B) Fold change in biofilm formation of ΔpslA over-expression
strains. Bars represent the average fold change in biofilm formation compared to the empty vector control strain, ΔpslA pJN105
(dashed line). Statistics and error bars are reported as in A. (C) Psl production in PAO1 pJN105 (top) and PAO1 over-expression
strains (bottom). The top panels represent Psl production in the wild-type empty vector control strain, PAO1 pJN105, while the
bottom panels represent Psl production in the over-expression strains, or as in the last bottom panel, the negative control strain
ΔpslA pJN105. At least 3 biological replicates were performed.
doi: 10.1371/journal.pone.0082621.g001
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translational fusions [17] and each over-expression construct.
Compared to the empty vector control strain, none of the over-
expression strains exhibited altered pslA transcription in either
exponential or stationary phase (Figure 2A). Similarly,
overexpression of PA1106, PA1323-24, PA1592, PA3691-92,
and PA5178 did not affect pslA translation at either growth
stage (Figure 2B). However, overexpression of phaF induced
an ~5-fold increase in pslA translation during stationary phase
(Figure 2B). Indeed, microarray analyses verified that psl
transcription did not change in the phaF over-expression strain
(Table S2). These data suggest that these genes/operons are
affecting Psl levels via at least 2 distinct pathways, as phaF is a
positive regulator of psl translation and the remaining 5 genes/
operons affect Psl production via other mechanisms.
Figure 2.  pslA transcription and translation in over-
expression strains.  (A) Fold change in the pslA
transcriptional response to gene over-expression. (B) Fold
change in the pslA translational response to gene over-
expression. β-galactosidase activity was measured at both
exponential (black bars) and stationary phase (white bars).
Bars represent fold change in pslA transcription or translation
compared to the empty vector control strain, PAO1 pJN105
(dashed line). While fold change in pslA transcription or
translation is reported for clarity, statistics were performed on
normalized luminesence values of empty vector control and
over-expression strains assayed on the same day (see
Materials and Methods). At least 3 biological replicates were
performed in duplicate. Error bars represent standard error of
the mean, n=3. *, P value < 0.05 by Student’s t test compared
to the empty vector control strain.
doi: 10.1371/journal.pone.0082621.g002
Psl production is enhanced in P. aeruginosa
chronological clinical isolates
The results described above suggest that over-expression of
PA1106, PA1323-24, PA1592, PA3691-92, phaF, and PA5178
induce Psl production in strain PAO1. In our previous study,
chronic P. aeruginosa CF isolates from 3 patients expressed all
of these genes at higher levels than their ancestor [10] (Table
S3). Therefore, we hypothesized that these chronic isolates
would increase Psl production relative to their ancestor strain.
To test this hypothesis, we used anti-Psl immunoblotting to
compare Psl production in P. aeruginosa chronological isolates
relative to their ancestors. In 18 chronic P. aeruginosa isolates
collected from 4 different patients, 13 (~72%) produced more
Psl than their corresponding ancestor (Figure 3). This
phenotype was expected for at least 5 isolates that showed
small colony formation on agar plates (small colony variant;
SCV; indicated in Figure 3), but only 4 showed enhanced Psl
production compared to the ancestor. Since enhanced Psl
production occurred in over 70% of the strains isolated during
the first ~40,0000 generations, we propose that enhanced
production of Psl is important during adaptation to the CF lung
environment.
Discussion
Since animal models do not manifest chronic P. aeruginosa
respiratory infections typical of human CF patients, adaptations
that improve in vivo fitness are difficult to identify. To overcome
this challenge, we used an evolutionary approach to identify
gene expression traits undergoing natural selection and then
characterized the phenotypes these genes impacted. Our
studies are similar to in vitro microbial evolution experiments
that have utilized transcriptomics and genomics to identify
beneficial adaptations that arise during standard laboratory
growth conditions [26,27]. The strength of these approaches
lies in analyzing chronological isolates that have undergone
selection, thereby allowing evolution to direct more targeted
genetic studies. Here, this powerful approach not only allowed
us to identify P. aeruginosa traits that are clinically significant,
but also illuminated the biological significance of genes with
unknown functions.
P. aeruginosa chronic CF infections are characterized by an
~40,000 generation adaptation period followed by genetic drift
and negative selection [2,3]. Due to the high incidence and
association of mucoidy with worsening disease symptoms,
many studies have focused on this phenotype [5,9,28]. Indeed,
alginate over-production leads to highly structured biofilms with
increased antibiotic resistance properties [6]. Here we propose
that a non-alginate exopolysaccharide, Psl, is equally important
as alginate during adaption to the CF lung. This is based on
our data showing that the 6 genes/operons undergoing parallel
evolution in vivo enhance Psl production, and over 70% of
chronic clinical isolates produce more Psl than their ancestor
strains during the first ~40,000 generations in vivo.
Furthermore, recent studies have shown that Psl is essential
for biofilm formation even in mucoid strains [29], and small
colony variants, characterized as over-producing Psl, can
undergo positive selection during chronic infection [30].
Pseudomonas aeruginosa Adaptation in the CF Lung
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While PA1106, PA1323-24, PA1592, PA3691-92, and
PA5178 enhance Psl production via an unknown mechanism,
phaF positively regulates psl translation. These data suggest a
model where at least 2 distinct pathways are undergoing
adaptive evolution resulting in enhanced Psl production. One
possible explanation for these findings is that each pathway
has additive fitness benefits, thereby allowing selection to act
on them separately. Indeed, in vitro evolution experiments have
shown that multiple genes affecting the same trait can gain
mutations that impact fitness [31,32]. While the benefit of
enhanced Psl production in vivo is unknown, it may be
important for antibiotic resistance or for avoiding the host
immune response, which has been demonstrated in vitro
[33,34].
Since the goal of this study was identify P. aeruginosa
phenotypes undergoing selection in vivo, we did not fully
investigate the molecular mechanisms of enhanced Psl
production in the PAO1 over-expression strains. PA1106,
PA1323-24, PA1592, PA3691-92, and PA5178 did not affect
Figure 3.  Psl production in clinical isolates from 4 patients
with CF.  Strains were grown in SCFM for ~16 hours and Psl
was extracted from whole cultures. Psl extracts were
normalized to equal protein concentrations for each patient and
subjected to immunoblot blot analyses as described in the
Materials and Methods. Each isolate is centered on its
corresponding number of in vivo generations (Table S3).
Isolates at time 0 are the ancestor. At least 3 biological
replicates were performed, and red boxes indicate isolates that
produced more Psl on average than the ancestor. SCV: small
colony variant.
doi: 10.1371/journal.pone.0082621.g003
either psl transcription or translation, while phaF enhanced psl
translation. One explanation for enhanced Psl production in the
PA1106, PA1323-24, PA1592, PA3691-92, and PA5178 over-
expression strains is that they have high levels of the small
signaling molecule bis-(3’,5’)-cyclic-dimeric-guanosine
monophosphate (cyclic-di-GMP), which can correlate with
increased Psl production without a corresponding increase in
psl transcription [35]. Additionally, phaF over-expression may
increase levels of two activators of psl translation, the small
non-coding RNAs RsmZ and RsmY. However, Northern blot
analyses demonstrated that neither RsmZ nor RsmY increased
expression in the phaF over-expression strain relative to the
empty vector control strain (Figure S3). Therefore, we
hyopthesize that phaF is acting independently of RsmZ and
RsmY, and we are currently investigating alternative
mechanisms of action.
Supporting Information
Figure S1.  Biofilm formation of PAO1 and PA14 strains
carrying the phaF expression construct. (A) Biofilm
formation of PAO1 strains carrying the phaF expression
construct. (B) Biofilm formation of PA14 strains carrying the
phaF expression construct. Biofilm formation was tested in the
empty vector control strain (black bar) and the phaF over-
expression strain (white bar) as described in the Materials and
Methods. At least 2 biological replicates were performed in
octuplicate. *, P value < 0.001 by Student’s t test compared to
the empty vector control strain. Error bars represent standard
error of the mean, n ≥ 16.
(TIF)
Figure S2.  Psl anti-sera specificity. Psl anti-sera specificity
was tested on PAO1 control strains grown as described in the
Materials and Methods. Psl- (strain WFPA800, a deletion of the
psl promoter in PAO1). pBAD-psl (strain WFPA801, psl
promoter is replaced with the pBAD promoter in PAO1). PAO1
pJN105 (the wild-type empty vector control strain). See Table
S4 for more strain information.
(TIF)
Figure S3.  RsmY and RsmZ expression in the empty
vector control (PAO1 pJN105) and phaF over-expression
strain. Strains were grown in MOPS buffered minimal media
supplemented with 0.5% glucose and 0.5% casamino acids for
~16 hours starting from OD=0.05. 15 μg total RNA was
separated on a 10% polyacrylamide-8 M urea gel, transferred
to nitrocellulose, and probed for RsmY or RsmZ (see Table S5
for probe sequences). Two biological replicates were
performed, and a representative is shown. PAO1 pJN105:
empty vector control strain; PAO1 phaF: phaF over-expression
strain.
(TIF)
Table S1.  Expression of the 15 up-regulated genes in
ancestors from 3 CF patients (A1, B1, and C1) compared to
PAO1.
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(DOCX)
Table S2.  Expression of the phaF over-expression strain
compared to the empty vector control strain.
(DOCX)
Table S3.  Clinical isolates analyzed in this study.
(DOCX)
Table S4.  Strains and plasmids used in this study.
(DOCX)
Table S5.  Primers and probes used in this study.
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